JP2023502323A5 - - Google Patents

Info

Publication number
JP2023502323A5
JP2023502323A5 JP2022524620A JP2022524620A JP2023502323A5 JP 2023502323 A5 JP2023502323 A5 JP 2023502323A5 JP 2022524620 A JP2022524620 A JP 2022524620A JP 2022524620 A JP2022524620 A JP 2022524620A JP 2023502323 A5 JP2023502323 A5 JP 2023502323A5
Authority
JP
Japan
Application number
JP2022524620A
Other languages
Japanese (ja)
Other versions
JPWO2021098757A5 (https=
JP2023502323A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/129992 external-priority patent/WO2021098757A1/en
Publication of JP2023502323A publication Critical patent/JP2023502323A/ja
Publication of JP2023502323A5 publication Critical patent/JP2023502323A5/ja
Publication of JPWO2021098757A5 publication Critical patent/JPWO2021098757A5/ja
Pending legal-status Critical Current

Links

JP2022524620A 2019-11-21 2020-11-19 抗tigit抗体との組合せで抗ox40抗体を用いる癌治療の方法 Pending JP2023502323A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/120033 2019-11-21
CN2019120033 2019-11-21
PCT/CN2020/129992 WO2021098757A1 (en) 2019-11-21 2020-11-19 Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies

Publications (3)

Publication Number Publication Date
JP2023502323A JP2023502323A (ja) 2023-01-24
JP2023502323A5 true JP2023502323A5 (https=) 2023-11-29
JPWO2021098757A5 JPWO2021098757A5 (https=) 2023-11-29

Family

ID=75980305

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022524620A Pending JP2023502323A (ja) 2019-11-21 2020-11-19 抗tigit抗体との組合せで抗ox40抗体を用いる癌治療の方法

Country Status (12)

Country Link
US (1) US20230002500A1 (https=)
EP (1) EP4061846A4 (https=)
JP (1) JP2023502323A (https=)
KR (1) KR20220103709A (https=)
CN (1) CN114746446A (https=)
AU (1) AU2020385499A1 (https=)
BR (1) BR112022009265A2 (https=)
CA (1) CA3157042A1 (https=)
IL (1) IL293118A (https=)
MX (1) MX2022006148A (https=)
WO (1) WO2021098757A1 (https=)
ZA (1) ZA202204422B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112566935B (zh) 2018-05-23 2024-12-13 百济神州有限公司 抗ox40抗体和使用方法
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Tigit及cd112r阻斷
AU2023305697A1 (en) * 2022-07-15 2025-02-20 Beigene Switzerland Gmbh Methods of cancer treatment using anti-tigit antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494107C2 (ru) * 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
EP3208612B1 (en) * 2008-04-09 2019-09-18 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
SMT201800503T1 (it) * 2013-03-18 2018-11-09 Janssen Pharmaceuticals Inc Anticorpi anti-cd (ox40) umanizzati e loro usi
AU2015327868A1 (en) * 2014-10-03 2017-04-20 Novartis Ag Combination therapies
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗-ox40抗體及其用途
KR20170072343A (ko) * 2014-11-06 2017-06-26 제넨테크, 인크. Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
TN2019000101A1 (en) * 2015-05-29 2020-07-15 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof.
GB201519481D0 (en) * 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
IL272227B2 (en) * 2017-07-27 2025-09-01 iTeos Belgium SA Anti-tigit antibodies
CN111542544A (zh) * 2017-11-01 2020-08-14 百时美施贵宝公司 用于治疗癌症的免疫刺激性激动性抗体
KR102769109B1 (ko) * 2017-11-24 2025-02-18 유큐(베이징) 바이오파마 코., 엘티디 항―ox40 항체 및 그의 용도
TWI816729B (zh) * 2017-12-30 2023-10-01 英屬開曼群島商百濟神州有限公司 抗tigit抗體及其作為治療和診斷的用途
CN110092832B (zh) * 2018-01-29 2020-03-31 康源博创生物科技(北京)有限公司 抗ox40抗体及其用途
CN112566935B (zh) * 2018-05-23 2024-12-13 百济神州有限公司 抗ox40抗体和使用方法

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)